from Breakingviews:

Overreaching enforcers redraw insider trading line

December 11, 2014

By Reynolds Holding

The author is a Reuters Breakingviews columnist. The opinions expressed are his own. 

from Morning Bid with David Gaffen:

The Market’s Silly Season

December 4, 2014

The meaningful part of the year is drawing to a close (near as I can see it, there's tomorrow's jobs report, the Fed meeting in two weeks, and, yep, that's about it), and as we head into the silly season for happenings in our markets, here's a laundry list of oddball things to consider:

from Breakingviews:

Steve Cohen’s loot could land in undeserving hands

November 11, 2014

By Reynolds Holding

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

from Morning Bid with David Gaffen:

Simple Tricks and Nonsense

October 10, 2014

Heading into the end of a violent week and ahead of a slew of earnings reports, the market has swung from one extreme to another, as the average daily move in the S&P 500 rises dramatically, as futures promise another big drop at the open Friday, and as investors try to take stock of what's happening here in their beloved stock market.

from Breakingviews:

Sears’ Canada stake sale merits a discount

October 3, 2014

By Kevin Allison

The author is a Reuters Breakingviews columnist. The opinions expressed are his own. 

from Counterparties:

Trimming the hedge funds

By Jordan Fraade
September 16, 2014

The California Public Employees Retirement System is getting out of hedge funds. Calpers’ decision to divest the $4 billion it had in hedge funds (of about $300 billion total) isn’t exactly a surprise, since members of the organization openly expressed doubts about the investment strategy last year. But Calpers’ reputation as the gold standard among public-employee pension funds may portend changes in the way smaller pension funds invest their money.

from Breakingviews:

Hedge-fund-free – the latest Californian fad?

September 16, 2014

By Richard Beales

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

from Counterparties:

MORNING BID – I was dreaming when I wrote this…

August 25, 2014

The move by Roche to buy biotech company Intermune for $8.3 billion at a 38 percent premium isn’t going to make Janet Yellen happy, given her thoughts on the valuation of certain biotechnology and Internet retailing names. Still, with the Fed chair on board for low rates for some time given the slack situation in the labor market that the Fedsters keep talking about (basically, the unemployment rate, like the old grey mare, ain’t what she used to be), the long march to 2,000 on the S&P looks like it’s probably going to be over before long (it's been done on an intraday basis, and now we're just waiting on a close above that level), representing a tripling in that average in a bit more than five years and raising again all those questions about whether this all makes sense and if anyone cares anyway.

from Breakingviews:

Argentine opportunity cost is reason to cut deal

July 29, 2014

By Martin Hutchinson

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

from Breakingviews:

Soros takes sub-quantum leap into activism

June 27, 2014

By Christopher Swann

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.